|Bid||18.50 x 5300|
|Ask||48.54 x 100|
|Day's Range||18.34 - 20.05|
|52 Week Range||4.03 - 22.00|
|PE Ratio (TTM)||-6.07|
|Earnings Date||Oct 31, 2017 - Nov 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||22.20|
Clinical trial results and FDA meetings expected in the near term could set these stocks up for big gains over the long run.
SOUTH PLAINFIELD, N.J., Sept. 21, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on September 18, 2017 it approved non-statutory stock options to purchase an aggregate of 32,500 shares of its common stock to thirteen new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on September 18, 2017 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to PTC Therapeutics, Inc. Here are 5 ETFs with the largest exposure to PTCT-US. Comparing the performance and risk of PTC Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)